SG95494G - Drug compositions stabilized against oxidation and discoloration - Google Patents

Drug compositions stabilized against oxidation and discoloration

Info

Publication number
SG95494G
SG95494G SG95494A SG95494A SG95494G SG 95494 G SG95494 G SG 95494G SG 95494 A SG95494 A SG 95494A SG 95494 A SG95494 A SG 95494A SG 95494 G SG95494 G SG 95494G
Authority
SG
Singapore
Prior art keywords
discoloration
against oxidation
stabilized against
drug compositions
compositions stabilized
Prior art date
Application number
SG95494A
Other languages
English (en)
Inventor
Kuchi Sury Murthy
Michael Ray Harris
Gerard Clifford Hokanson
Robert George Reisch Jr
Mahdi Bakir Fawzi
Frank Stanley Waldman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25445868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG95494(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to SG95494A priority Critical patent/SG95494G/en
Publication of SG95494G publication Critical patent/SG95494G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
SG95494A 1986-10-20 1994-07-15 Drug compositions stabilized against oxidation and discoloration SG95494G (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG95494A SG95494G (en) 1986-10-20 1994-07-15 Drug compositions stabilized against oxidation and discoloration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/921,717 US4830853A (en) 1986-10-20 1986-10-20 Drug compositions stabilized against oxidation
SG95494A SG95494G (en) 1986-10-20 1994-07-15 Drug compositions stabilized against oxidation and discoloration

Publications (1)

Publication Number Publication Date
SG95494G true SG95494G (en) 1994-10-28

Family

ID=25445868

Family Applications (1)

Application Number Title Priority Date Filing Date
SG95494A SG95494G (en) 1986-10-20 1994-07-15 Drug compositions stabilized against oxidation and discoloration

Country Status (20)

Country Link
US (1) US4830853A (de)
EP (1) EP0264887B1 (de)
JP (1) JP2703906B2 (de)
KR (1) KR960000430B1 (de)
AT (1) ATE67090T1 (de)
AU (1) AU604061B2 (de)
CA (1) CA1297024C (de)
DE (1) DE3772924D1 (de)
DK (1) DK174916B1 (de)
ES (1) ES2040726T3 (de)
FI (1) FI100091B (de)
GR (1) GR3002698T3 (de)
HK (1) HK85694A (de)
IE (1) IE60773B1 (de)
NO (1) NO874352L (de)
NZ (1) NZ221954A (de)
PH (1) PH25582A (de)
PT (1) PT85942B (de)
SG (1) SG95494G (de)
ZA (1) ZA877132B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
YU48602B (sh) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Postupak za dobijanje stabilne formulacije soli enalaprila
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
ES2559766T3 (es) * 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
HUP0102260A3 (en) * 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
WO2003059330A1 (en) * 2002-01-15 2003-07-24 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
ATE424192T1 (de) * 2003-06-26 2009-03-15 Teva Pharma Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
AU2003300692A1 (en) * 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
MX2008013374A (es) * 2006-04-19 2008-11-12 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3.0]-octano-3-carboxilico.
US8017168B2 (en) * 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
KR100808132B1 (ko) 2007-03-02 2008-02-29 고천일 음식물쓰레기 소멸처리장치
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
WO2012085249A2 (en) * 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
SI3193826T1 (sl) 2014-07-31 2019-02-28 Pharmathen S.A. Orodisperzibilen filmski sestavek, ki obsega enalapril, za zdravljenje hipertenzije pri pediatrični populaciji
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US20180325813A1 (en) 2015-11-07 2018-11-15 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
JP7482777B2 (ja) 2018-01-11 2024-05-14 バイロファーマ バイオロジクス エルエルシー 安定なコルチコステロイド組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (de) * 1957-07-17
US3697641A (en) * 1970-01-02 1972-10-10 Gerhard W Ahrens Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
DE3175410D1 (en) * 1980-07-29 1986-11-06 Sanofi Sa Acid stabilized compositions of thieno-pyridine derived compounds and process for preventing degradation of such compounds
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4442089A (en) * 1982-07-06 1984-04-10 E. R. Squibb & Sons, Inc. Method for treating glaucoma with topical or systemic ACE inhibitor compositions
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration

Also Published As

Publication number Publication date
HK85694A (en) 1994-08-26
AU604061B2 (en) 1990-12-06
FI100091B (fi) 1997-09-30
NO874352L (no) 1988-04-21
DK543587D0 (da) 1987-10-16
GR3002698T3 (en) 1993-01-25
JPS63104931A (ja) 1988-05-10
JP2703906B2 (ja) 1998-01-26
EP0264887B1 (de) 1991-09-11
FI874594L (fi) 1988-04-21
KR880004811A (ko) 1988-06-27
ATE67090T1 (de) 1991-09-15
AU7939787A (en) 1988-04-21
PT85942B (pt) 1990-07-31
KR960000430B1 (ko) 1996-01-06
PH25582A (en) 1991-08-08
IE60773B1 (en) 1994-08-10
FI874594A0 (fi) 1987-10-19
DK174916B1 (da) 2004-02-23
CA1297024C (en) 1992-03-10
ZA877132B (en) 1989-04-26
EP0264887A1 (de) 1988-04-27
ES2040726T3 (es) 1993-11-01
US4830853A (en) 1989-05-16
DE3772924D1 (de) 1991-10-17
PT85942A (en) 1987-11-01
DK543587A (da) 1988-04-21
NZ221954A (en) 1990-03-27
NO874352D0 (no) 1987-10-19
IE872550L (en) 1988-04-20

Similar Documents

Publication Publication Date Title
GR3002698T3 (en) Drug compositions stabilized against oxidation and discoloration
GR3002454T3 (en) Stabilized drug compositions
ZA88382B (en) Stabilized compositions
EP0534396A3 (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
GR3026222T3 (en) Novel mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
ZA875947B (en) Pharmaceutical compositions containing dipyridamole or mopidamol and o-acetylsalicylic acid
GB8820174D0 (en) Quinoline compound
GB8830226D0 (en) Novel compounds